Compare 3M Company (MMM) vs Pfizer Inc (PFE) Price & Performance

3M (MMM) trades at $162.12, down 0.93% on the day, with a bearish technical signal and support near $158. The company reported strong Q2 2026 earnings, beating estimates with 5.4% organic growth and a 24.9% adjusted operating margin. Revenue for 2025 was $24.95B with net income of $3.25B, though margins have compressed from prior years. Analysts are mixed with a consensus price target of $191, representing potential upside, but high debt and weak consumer sales pose challenges.

The outlook for MMM is cautiously optimistic amid a genuine turnaround narrative. Investment opportunities include continued operational execution, shareholder returns via dividends and buybacks, and growth in industrial and electronics segments. Key risks involve persistent consumer segment weakness, litigation overhang from PFAS, and macroeconomic pressures affecting demand. The stock's valuation remains elevated with a P/E of 29.06, requiring sustained earnings growth to justify further gains.

Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.

The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.